Latest News - Page 4

Prison Study to Focus on Substance Use and Hepatitis C Treatments
BY CATHERINE KOLONKO
A group of health professionals and researchers have received grants to study treatments for substance use disorders and hepatitis C among people incarcerated in state prisons.
Hepatitis C Screening Gaps Found Among Eligible Patients
BY CATHERINE KOLONKO
An estimated 3 million people in the United States are chronically infected with HCV.
Hep C: Interferon Treatment Triggers Anti-Interferon Antibodies
BY DAVA STEWART
Development of antibodies found most likely responsible for at least part of the non-response rates in a population of difficult-to-treat HCV patients.
Trials Set to Evaluate AbbVie's Experimental HCV Regimen
BY LAUREN SANTYE, ASSISTANT EDITOR
Pair of daily ribavirin-free oral drugs will be analyzed in patients with hepatitis C genotypes 1-6.
A Patient's Long, Difficult Journey to a Cure for Hepatitis C
BY LAUREN SANTYE, ASSISTANT EDITOR
Burdened by the symptoms of hepatitis C, an Australian man faced an uncertain future before new antiviral drugs offered hope.
Improving Screening for HCV in Community Health Centers
BY BRENNA DIAZ
A recent study analyzed screening procedures of community health centers and was able to quantify the screening gap for hepatitis C according to gender and race/ethnicity.
Total Joint Arthroplasty in the Hepatitis C Patient
BY JEANNETTE Y. WICK, RPH, MBA, FASCP
Study indicates orthopedic surgeons be mindful of the potential for increased risks with hepatitis C patients.
Two Potentially Hepatoprotective Agents Proved Compatible With Technivie
BY MICHAEL R. PAGE, PHARMD, RPH
Use of these hepatoprotective agents may reduce the risk of liver damage caused by ingredients in Technivie and Viekira Pak.
$auto_registration$